The Conversation (0)
- WORLD EDITIONAustraliaNorth AmericaWorld
Chart
Detailed Quote
Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics by building a differentiated portfolio of injectable brands that address the evolving needs of practitioners and patients. Our portfolio includes Jeuveau (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, Evolysse, a collection of unique injectable hyaluronic acid (HA) gels, and Profhilo, the market-leading injectable for skin quality in Europe, which Evolus has exclusively licensed for development and commercialization in the United States.
Featured Articles and Interviews
Nov 10, 2026
Top 5 Small-cap Biotech Stocks in 2026
Press Releases
Dec 19, 2018
Evolus Added to NASDAQ Biotechnology Index
Aug 17, 2018
Evolus Granted Approval of DWP-450 by Health Canada
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
